Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...
The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...
A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...
"Tumor behavior upon recurrence is often more aggressive, and patients may quickly exhaust safe and effective options for ...
The Centers for Medicare & Medicaid Services (CMS) has added several changes to the Medicare price negotiation process ...
AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE ® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...
Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00.
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
15h
Bill Gates visiting TerraPower Isotopes, the subsidiary of the nuclear power company TerraPower that he helped found. Gates ...
Santa Barbara, Calif.– 2024 October 2 –Rupa Dainer, MD, U.S. Navy veteran and medical director, senior patient safety physician of ...
After 19 weeks on daily oral HU6 treatment, people shed on average 2.9 kg (~6.3 lb) or 2.7% of their starting body weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback